Cytophage Technologies Ltd. · LS:A4ZZ0X
Cytophage Technologies — Investor Presentation (April 2024)
21 slides from Cytophage Technologies's investor presentation, April 2024
Slide 1: Investor Presentation April 2024
Investor Presentation April 2024 1
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Certain information set forth in this presentation contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except fo
Slide 3: The Problem: Antibiotic Use in Food Chain Threatens Human Health
THE PROBLEM USE OF ANTIBIOTICS IN • Over time, the use of antibiotics creates resistance in the FOOD CHAIN THREATENS bacteria they are meant to treat. This is known as antimicrobial resistance (AMR) HUMAN HEALTH • WHO: predicts by 2050 AMR will be the leading cause of human mortality • 70% of antibi
Slide 4: Bacteriophages – Natural Predators
BACTERIOPHAGES – NATURAL PREDATORS Bacteriophage are viruses that only infect and kill bacteria Phages are most abundant form of life on earth (nature's version of antibiotics) CYTOPHAGE is improving bacteria’s natural predators for commercially applicable solutions. How (Cytophage) bacteriophages w
Slide 5: Cytophage – "Killer" Solution
CYTOPHAGE – “KILLER” SOLUTION Cytophage Tools Cytophage Phages Cytophage Manufacturing - Safe and toxin free - Lytic life cycle only GMP facility Natural phage - 1000’s of strains in under construction Cytophage library Large scale manufacturing - Remove bacteria defenses capacity Environmental - Ta
Slide 6: Cytophage – Reasons to Buy
CYTOPHAGE – REASONS TO BUY The “Killer” Solution to a global food problem Near term commercial sales with strong margins De-risked, replicable technology 6
Slide 7: Go To Market Strategy: Animal Health and Human Health
GO TO MARKET STRATEGY PART 1 PART 2 ANIMAL HEALTH HUMAN HEALTH Faster Trials Long timeframe without regulatory red tape FDA trial phases seen as only benchmark of success -- yet trial can be timeframe of 7 - 10 years Lower Trial Costs Capital Intensive (compared to human trials) Capital intensive pr
Slide 8: Cytophage History
CYTOPHAGE HISTORY Founded 2016 Leading scientific staff recruited from Canada’s National Microbiology Lab in Winnipeg Research & Continued focus on modifying and transforming phages into commercial phage solutions Development Prestigious Competitive Wins • Two filed patents, additional will be filed
Slide 9: De-risking Cytophage
DE-RISKING CYTOPHAGE Value Proposition with First Trials Completed Patent Applications Global Relevance with Outstanding Results Two pending patents surrounded by proprietary trade secrets Concerns of anti-microbial resistance Double digit percentage improvements Patent development around phage have
Slide 10: Replacing Antibiotics in $1BN Poultry Industry
CYTOPHAGE’S STRATEGIC MARKET ENTRY REPLACING ANTIBIOTICS IN $1BN POULTRY INDUSTRY • ~100BN CHICKENS AND 1.5T CHICKEN EGGS In 2020, ~100Bn Chickens and 1.5T chicken eggs were produced globally* Market Trends • Poultry meat and eggs are among the animal- • $4.68BN USD (~80-90% OF BIRDS) source foods m
Slide 11: Commercialization Strategy
COMMERCIALIZATION STRATEGY Commercialization: International • Initial Distribution Partner: Renata Ltd • 80 year history – publicly traded • >$1Bn US Market Cap • ~$400M US annual revenue • #1 Market share in animal health • Former SE Asia division of one of the largest global pharmaceutical compani
Slide 12: 2020 Global Chicken and Egg Production (FAO)
South Korea COMMERCIALIZATION LANDSCAPE 2020 GLOBAL CHICKEN AND EGG PRODUCTION (FAO) (In Millions) Annual Global Production: ~100 billion Chickens and ~1.5 trillion Eggs South Korea CHICKEN PRODUCTION USA Myanmar 3,429 EGG PRODUCTION CHICKEN CHICKEN PRODUCTION PRODUCTION 3,480 9,212 Bangladesh 808.2
Slide 13: Animal Health Division – Four Pillars
ANIMAL HEALTH DIVISION – FOUR PILLARS – Broilers Carcass/Meat AviPhage Future market Initial Target Market Eggs Salmonella / E.coli Trial: June 2023 Layers OvaPhage Future market Initial Target Market Salmonella / Shingella Trial: Q2/Q3 2024 13
Slide 14: June 2023 – Results of Chicken Broiler Trial
June 2023 – RESULTS OF CHICKEN BROILER TRIAL FarmPhageTM outperformed untreated sample group across the three most critical metrics FarmPhageTM feed conversion ratio of 1.55 was on par with typical antibiotic feed conversion ratio (1.52) Untreated FarmPhage Sale Date 13/06/2023 11/06/2023 Batch Size
Slide 15: Cytophage Laboratory In-Vitro Testing: Eggs
CYTOPHAGE LABORATORY IN-VITRO TESTING: EGGS Salmonella Recovered (%) Shigella Recovered (%) 100.00 100.00 75.00 99% 75.00 99% reduction reduction 50.00 50.00 25.00 25.00 0.71% 0.65% 0.00 0.00 Salmonella Bacterial Control Ovaphage Treated Shigella Bacterial Control Ovaphage Treated Shigella is an int
Slide 16: Growth Model and Potential Catalysts
GROWTH MODEL AND POTENTIAL CATALYSTS Cytophage PRODUCT SETS 2023 2024 2025 Target Market POULTRY – Broiler Chickens Catalysts & Milestones $40M + POULTRY - Eggs Results from human N of 1 trial $40M + OvaPhage/Egg wash in field testing – REPLICABLE DAIRY COWS - Mastitis end of March 2024 $50M + T
Slide 17: Human Health Division
HUMAN HEALTH DIVISION BACTERIAL INFECTIONS (Classic Phage Therapy): • Targeted bacterial phage to treat human AMR infections • Current treatments under SAP (special access program) • First phage treatment in patient with prosthetic joint infection Feb 2024 (N of 1 trial) 17
Slide 18: Capital Structure
CAPITAL STRUCTURE Capitalization (CYTO.V) Shares Outstanding 53,753,346 Options Outstanding 5,188,875 Warrants Outstanding 7,114,165 Fully Diluted S/O 66,045,386 Options Warrants Strike: <$0.28 2,000,000 Strike: $0.50 - $1.40* 7,114,165 Strike: $0.65 - $1.30* 3,188,875 Total 5,188,875 * Currently ou
Slide 19: Management
LEADERSHIP TEAM BOARD OF DIRECTORS HAROLD WOLKIN, MANAGEMENT DR. STEVEN THERIAULT HEATHER MEDWICK MICHAEL GRAHAM JULIUS KALCEVICH CHAIRMAN CHIEF EXECUTIVE OFFICER & CHIEF OPERATING OFFICER CHIEF COMMERCIAL OFFICER CHIEF FINANCIAL OFFICER DR. STEVEN THERIAULT CHIEF SCIENCE OFFICER • MPA, focus on hea
Slide 20: Appendix
APPENDIX CYTOPHAGE.COM 20
Slide 21: June 2023 Trial – Visible Improvements Within Days
June 2023 TRIAL - VISIBLE IMPROVEMENTS WITHIN 11 DAYS Day 3 Day 11 Day 11 Untreated 21
Cytophage Technologies — Investor Presentation (April 2024) on 6ix